Key Takeaway
Explore what clinical trial data reveals about lean mass preservation on retatrutide, how its glucagon receptor activity may help, and strategies to protect muscle during treatment.
Like other GLP-1 class medications, some lean mass loss occurs alongside fat loss with retatrutide, though the glucagon receptor component may help preserve muscle better than single-agonist drugs. This is one of the most important questions in the obesity pharmacology space right now, and retatrutide's unique triple-agonist design makes its body composition profile particularly interesting to researchers and clinicians alike.
The Lean Mass Problem in Weight Loss
Every form of weight loss, whether through diet, exercise, surgery, or medication, results in some loss of lean body mass alongside fat. This is a fundamental reality of caloric deficit. The typical ratio during conventional dieting is roughly 75% fat loss to 25% lean mass loss. Bariatric surgery tends to produce similar or slightly worse ratios. The goal of modern obesity treatment is to shift that ratio as far toward pure fat loss as possible.
Lean mass includes muscle, bone, water, and organ tissue. When people talk about "muscle loss" with weight loss medications, they're usually referring to the lean mass component measured by DEXA scans in clinical trials. Not all lean mass loss is muscle. Some is water bound to glycogen stores, some is the structural tissue that supported a larger body frame, and some is genuinely functional skeletal muscle. The clinical significance depends heavily on which compartments are losing mass.
What Semaglutide and Tirzepatide Showed
To understand where retatrutide fits, it helps to look at the body composition data from its predecessors. In the STEP 1 trial[1], semaglutide 2.4mg produced approximately 15% total body weight loss over 68 weeks. DEXA sub-studies showed that roughly 40% of the weight lost was lean mass, which was higher than the historical 25% benchmark and raised legitimate concerns.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
Tirzepatide performed somewhat better in the SURMOUNT trials. At the highest dose (15mg), participants lost about 22.5% of body weight[2], with lean mass accounting for approximately 25-33% of the total loss depending on the sub-study. The addition of the GIP receptor appeared to offer some lean mass protection compared to GLP-1 alone, though the data was not definitive.
These numbers sparked an important conversation in obesity medicine about whether medications that produce dramatic weight loss might leave patients metabolically weaker despite being lighter.
Retatrutide's Theoretical Advantage
Retatrutide adds a third receptor to the equation: the glucagon receptor. This is where the body composition story gets genuinely compelling. Glucagon has well-established effects on energy metabolism that differ fundamentally from GLP-1 and GIP.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Glucagon stimulates lipolysis, the breakdown of stored fat into free fatty acids for energy use. It also increases thermogenesis, meaning the body burns more calories as heat rather than storing them. Critically, glucagon's primary metabolic targets are adipose tissue and the liver, not skeletal muscle. In animal studies, glucagon receptor agonism has been shown to preferentially drive fat oxidation while relatively sparing lean tissue.
The theory is that by activating the glucagon receptor alongside GLP-1 and GIP, retatrutide creates a metabolic environment where the body draws more heavily from fat stores and less from muscle to meet its energy needs during a caloric deficit. This would show up in clinical data as a more favorable fat-to-lean mass loss ratio.
What the Phase 2 Trial Actually Showed
The Phase 2 trial of retatrutide, published in the New England Journal of Medicine, focused primarily on weight loss efficacy and safety rather than detailed body composition. Participants on the 12mg dose lost an average of 24.2% of body weight over 48 weeks[3], the largest weight reduction ever recorded for an obesity medication.
Body composition data from the trial was limited. DEXA was not performed on all participants, and the sub-study results that were shared suggested a lean mass loss percentage in the range of 25-30% of total weight lost. This is broadly comparable to tirzepatide and meaningfully better than the semaglutide STEP 1 numbers, though direct cross-trial comparisons should be interpreted cautiously.
The Phase 3 trials, which are ongoing, are expected to provide much more strong body composition data. Eli Lilly has acknowledged the importance of this question and has included DEXA endpoints in the larger studies. Until those results are published, any claims about retatrutide's superiority in lean mass preservation remain theoretical.
Practical Strategies to Protect Muscle
Regardless of which medication you use, the evidence is clear that patients can significantly influence their lean mass outcomes through lifestyle choices during treatment.
Resistance training is non-negotiable. The single most effective intervention for preserving muscle during weight loss is progressive resistance exercise. Studies consistently show that patients who engage in structured strength training two to four times per week during GLP-1 therapy retain substantially more lean mass than those who don't exercise. You don't need a gym membership or complex programs. Bodyweight exercises, resistance bands, or basic free weights performed consistently will send the signal your muscles need to resist atrophy.
Protein intake must be deliberately high. The appetite suppression from retatrutide can make it difficult to eat enough, and when patients do eat, they often gravitate toward easy, low-protein options. This is a mistake. Aim for 1.0 to 1.2 grams of protein per kilogram of body weight as an absolute minimum, and closer to 1.6 grams per kilogram if you're actively strength training. Prioritize protein at every eating occasion. If solid food is difficult due to nausea or reduced appetite, protein shakes, Greek yogurt, and cottage cheese can fill the gap.
Don't let calories drop too low. There's a point of diminishing returns with caloric restriction. Below approximately 1,000 to 1,200 calories daily for most adults, the body accelerates lean mass breakdown to meet its basic metabolic needs. If retatrutide's appetite suppression is so strong that you're consistently eating below this threshold, talk to your prescriber about dose adjustment. More aggressive weight loss isn't always better weight loss.
Consider creatine supplementation. Creatine monohydrate is one of the most studied supplements in exercise science and has strong evidence supporting its role in muscle preservation and function. Taking 3-5 grams daily alongside resistance training may provide additional lean mass protection during weight loss. It's safe, inexpensive, and widely available.
Sleep and recovery matter. Muscle repair and growth happen primarily during sleep. Growth hormone, which matters in lean tissue maintenance, is released predominantly during deep sleep stages. Patients who are chronically sleep-deprived lose more lean mass during caloric restriction than those who sleep seven to nine hours per night. Prioritize sleep as a core component of your body composition strategy.
The Long View on Body Composition
The muscle loss conversation often misses an important nuance. Carrying 250 or 300 pounds requires more muscle mass just to move through daily life. When someone loses 50 or 60 pounds, they simply need less structural muscle to support their frame. Some of the measured lean mass loss is the body naturally right-sizing itself for a lighter body. This isn't pathological. It's adaptive.
What matters clinically is functional capacity. Can you walk farther, climb stairs more easily, carry groceries without strain? If your strength and endurance are improving even as the scale and DEXA show some lean mass reduction, you're likely in good shape. The patients who need to worry are those who lose weight without exercising and notice declining physical function, weakness, or difficulty with daily activities.
Retatrutide's triple-agonist mechanism gives it a theoretical edge in body composition, but the biggest determinant of how much muscle you keep will always be what you do in the gym and the kitchen. The medication handles appetite and metabolic efficiency. The rest is up to you.
Medical References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]